Show simple item record

dc.contributor.authorThatcher, Nick
dc.contributor.authorNiven, Robert McL
dc.contributor.authorAnderson, Heather
dc.date.accessioned2010-04-08T14:35:45Z
dc.date.available2010-04-08T14:35:45Z
dc.date.issued1996-05
dc.identifier.citationAggressive vs nonaggressive therapy for metastatic NSCLC. 1996, 109 (5 Suppl):87S-92S Chesten
dc.identifier.issn0012-3692
dc.identifier.pmid8635395
dc.identifier.urihttp://hdl.handle.net/10541/96020
dc.description.abstractClinicians tend to underestimate potential modest benefits of chemotherapy. They are often reluctant to refer patients for chemotherapy, perhaps because they expect the side effects to outweigh any perceived benefits. However, patients are much more ready to accept chemotherapy, even when the likely benefits are small. Quality of life, change in performance status, and relief of tumor-related symptoms are important additional parameters of treatment assessment. Taking account of these other factors will help clinicians balance quality and quantity of life in patients with metastatic non-small cell lung cancer.
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshClinical Trials as Topic
dc.subject.meshHealth Status
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshQuality of Life
dc.subject.meshSurvival Rate
dc.subject.meshTreatment Outcome
dc.titleAggressive vs nonaggressive therapy for metastatic NSCLC.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK.en
dc.identifier.journalChesten
html.description.abstractClinicians tend to underestimate potential modest benefits of chemotherapy. They are often reluctant to refer patients for chemotherapy, perhaps because they expect the side effects to outweigh any perceived benefits. However, patients are much more ready to accept chemotherapy, even when the likely benefits are small. Quality of life, change in performance status, and relief of tumor-related symptoms are important additional parameters of treatment assessment. Taking account of these other factors will help clinicians balance quality and quantity of life in patients with metastatic non-small cell lung cancer.


This item appears in the following Collection(s)

Show simple item record